Abstract
Background: Although immune checkpoint inhibitors have opened a new mode of treatment for solid tumors, their efficacy in nasopharyngeal carcinoma (NPC) needs to be further investigated. Inhibitors of the PD-1/PD-L1 immune checkpoint are one of the hot topics in tumor immunotherapy. Programmed death ligand-2 (PD-L2) is a less studied ligand of PD-1 and has not yet been fully explored, especially in NPC. Understanding the clinical significance of PD-L2 expression, together with immune cell infiltration, might provide clues for biomarker screening in NPC immunotherapy. This study aimed to evaluate the role of PD-L2 as a prognostic factor for NPC patients as well as its role in immune regulation.
Methods: Immunohistochemistry (IHC) was performed on a tissue microarray including 557 NPC specimens using PD-L2 antibody. The immune cell markers CD4, FOXP3 and CD68 were also stained and quantified. The expression of PD-L2 exhibited different spatial patterns among NPC tumor and stromal tissues.
Results: A total of 90.8% of the cases showed membranous PD-L2 expression in tumors, and 80.8% showed membranous PD-L2 expression in stromal tissue. High stromal expression of PD-L2 predicted favorable overall and disease-free survival of NPC patients and was negatively correlated with tumor size, recurrence or metastasis and clinical stage. In contrast, high tumor abundance of PD-L2 correlated with poor disease-free survival, but had no obvious correlation with clinicopathological parameters. Multivariate analysis indicated that stromal PD-L2 was an independent and favorable prognostic factor. Furthermore, we found a positive correlation between stromal PD-L2 expression and the infiltration of CD68+ macrophages and CD4+Foxp3+ Treg cells in NPC stromal tissues (Pearson correlation=0.181 and 0.098, respectively).
Conclusions: Our results suggest that different PD-L2 expression patterns have distinct predictive values. PD-L2 expressed on stromal cells might play a role in the regulation of NPC progression, and involve in immune activation in the tissue microenvironment and have an independent good prognosis for NPC patients.
Introduction
NPC is one of the most common head and neck malignancies and is highly prevalent in Southeast Asia, North Africa and southern China 1. It is characterized by Epstein-Barr virus (EBV) infection and heavy lymphocyte infiltration 2. Seventy percent of NPC patients have locally advanced disease at the first diagnosis. The wide use of intensity-modulated radiotherapy and the optimization of chemotherapy strategies have dramatically improved treatment outcomes and overall prognosis over the past few decades 3. However, they have a limited effect on patients with locally advanced or distantly metastatic disease, and approximately 30% of high-risk patients still experience tumor recurrence, with distant metastasis as the primary failure pattern 4.
Nevertheless, the unique immune environment of EBV-associated NPC indicates the potential benefits of immunotherapy based on immune checkpoint inhibitors (ICIs). Programmed cell death-1 (PD-1) is mainly expressed on activated T cells and acts as an immune activation reaction of tumors after the combination of inhibitory receptor and ligand (PD-L1). In recent years, the application of inhibitors targeting PD-1 and PD-L1 in solid tumors has made substantial progress. In several clinical trials exploring the role of PD-1/PD-L1 inhibitors in NPC, Fang W, Ma B and Hsu C showed a good objective response rate with immune checkpoint inhibitors in patients with recurrent or metastatic NPC 5-7. Furthermore, in Fang et al.'s report, camrelizumab (anti-PD-1 antibody) monotherapy combined with chemotherapy has made promising progress in the first-line treatment of recurrent and metastatic NPC 5. However, anti-PD-1therapies are effective in only 20~30% of NPC patients 5,7. Moreover, following the administration of immune checkpoint inhibitors, an unexpected pattern of response designated hyperprogression may be observed in certain patients, ranging between 4 and 29% 8. These results indicated that the tumor microenvironment is intricate and that other immune checkpoints might exist. Understanding the clinical significance of the ICI-associated tumor microenvironment might provide clues for biomarker screening in NPC immunotherapy.
PD-1 has two ligands: PD-L1 and programmed death ligand-2 (PD-L2). PD-L1 is the main ligand for PD-1 and is one of the major targets for cancer immunotherapy. Multiple studies are available on the clinical significance of PD-1/PD-L1 in NPC, and the prognostic value remains controversial. Meta-analysis and IHC analysis showed that PD-L1 overexpression in NPC was associated with poor overall survival (OS) 9-10. Some retrospective analyses found that PD-L1 expression in immune cells is a favorable prognostic factor for NPC 11. However, another meta-analysis revealed that PD-L1 expression in NPC did not correlate with OS, and no statistically significant differences existed between the expression level of PD-1 in tumor infiltrating lymphocytes (TILs), which indicated that higher/positive expression of PD-L1/PD-1 may not serve as suitable biomarkers for the prognosis of NPC 12. In comparison to PD-L1, PD-L2 is a less studied ligand of PD-1. Some scholars believe that PD-L2 may be a potential therapeutic response marker of head and neck squamous cell carcinoma 13-14. However, to date, the expression and role of PD-L2 in NPC have yet to be fully explored.
Here, to explore the role of PD-L2 in the NPC tumor microenvironment, we first examined PD-L2 expression in NPC tumor cells and stromal cells using the IHC method. Second, we analyzed the correlation between the PD-L2 expression level and the clinical factors and outcomes of NPC patients. Finally, we evaluated the possible immune-regulatory function of PD-L2 on CD68+ macrophages and CD4+Foxp3+ Treg cells in the tumor microenvironment in NPC.
Patients and methods
Patients and clinical tissue samples
In this study, 557 NPC specimens were collected at the Department of Pathology, Sun Yat-Sen University Cancer Center (SYSUCC), Guangzhou, China, between January 2001 and December 2003. The inclusion criteria of patients and follow-up were the same as those in previous publications 15. All patients were treated with standard curative radiotherapy, with or without chemotherapy. The Institute Research Medical Ethics Committee of Sun Yat-Sen University granted approval for this study.
Tissue microarray construction
Paraffin-embedded specimens were obtained from a previously constructed tissue microarray (TMA) 16. Briefly, the paraffin-embedded tissue blocks and the corresponding hematoxylin and eosin (H&E)-stained slides were overlaid for TMA sampling. Duplicates of 1.0 mm diameter cylinders were punched from representative tumor areas of individual tissue blocks and re-embedded into a recipient paraffin block at a defined position using a tissue arraying instrument (Beecher Instruments, Silver Spring, MD).
IHC and evaluation
IHC was performed to examine PD-L2, CD68, CD4 and Foxp3 expression in NPC tissue specimens. Primary antibodies against PD-L2 (1:500 dilution, ab214221, Abcam, USA), CD4 (1:500 dilution, ab183685, Abcam, USA), Foxp3 (1:200 dilution, AF3240, USA), and CD68 (1:500 dilution, ABIN370601, Dako, Denmark) were used in this study. Formalin-fixed paraffin-embedded tissue specimens were processed in tissue microarrays with cores of 2 mm diameter. CD4+ antibodies were used to identify T lymphocytes (TIL, red membranous staining), and FoxP3 antibodies were used to identify regulatory T cells (Treg, brown nuclear staining). Immunohistochemistry was performed as double staining using a CD4-specific antibody and a FoxP3-specific antibody. For detection, a Polymer-Kit and Fast Red and Polymer-Kit and Fast brown (EnVision +Dual Link Kit) were used according to the manufacturer's instructions. The IHC results were evaluated and scored as described previously 16. In addition, the numbers of CD68+ macrophages and CD4+Foxp3+ Treg cells in the tumor and stroma were counted within the areas of 6 high-power fields (400X).
Selection of cutoff score
Receiver operating characteristic (ROC) curve analysis was performed to determine the cutoff score for a “high expression” designation with the 0,1-criterion implemented in SPSS software 16. First, the clinicopathologic characteristics were dichotomized into the following groups: T classification (T1-T2 versus T3-T4), N classification (N0 versus N1-N3), clinical stage (I-II versus III-IV), cancer progression (Yes versus No) and survival status (death due to NPC versus censored). Second, the expression scores for PD-L2 were trained in the ROC analysis. The cutoff score is the point on the curve that has both maximum sensitivity and specificity 16-17.
Statistical analysis
Statistical analysis was performed using SPSS (version 23.0; SPSS, Chicago, IL). The survival time was calculated monthly, and the OS time was calculated from the date of initial diagnosis to the date of death or the last follow-up. The χ2 test or Fisher's exact probability method was used for comparisons between groups. The survival rate was analyzed by Kaplan-Meier and log-rank methods. The Cox regression model was used for multivariate analysis. Associations between PD-L2 expression and the number of CD68+ macrophages or CD4+Foxp3+ Treg cells were examined by using Pearson correlation and independent t tests. P<0.05 was regarded as statistically significant.
Results
Patient characteristics
Among the 557 patients, 415 (74.5%) were male, and the median age was 46 years (range 19-78 years). Among these patients, 139 patients (25.0%) were diagnosed with nonkeratinizing differentiated carcinoma (NKDC), and 402 patients (72.2%) were diagnosed with nonkeratinizing undifferentiated carcinoma (NKUC), 16 patients (2.8%) were diagnosed with keratinizing squamous cell carcinoma (KSCC). One hundred forty-seven patients (26.4%) were in stage I and stage II, and 410 patients (73.6%) were in stage III and stage IV. The median follow-up time was 58.63 months (range 2 to 99 months). Of all the patients, 184 (33.0%) died, and 208(37.3%) presented with disease progression during the five-year follow-up period. Detailed clinical information is shown in supplemental Table 1.
Expression of PD-L2 in NPC tumor tissues
The expression of PD-L2 protein was determined in 557 NPC tumors from which five-year follow-up information was available by using IHC with the specific antibody. Overexpression of PD-L2 was observed in the membrane of NPC cells with different intensities (Figure 1). A total of 90.8% of the cases showed membranous PD-L2 expression in NPC tumor tissue (Figure 1A-D) and 80.8% of the cases showed membranous PD-L2 expression in stromal tissue (Figure 1E-H). Immunoreactivity for PD-L2 was scored for subsequent evaluation of its predictive value in NPC.
Figure 1.
Expression of PD-L2 in NPC tumor and stoma tissues. A and B Weak PD-L2 staining in NPC tumor tissues of TMA samples under low and high magnifications; C and D Strong PD-L2 staining in tumor tissues is shown under low and high magnifications; E and F Weak PD-L2 staining in NPC stoma tissues of TMA samples under low and high magnifications; G and H Strong PD-L2 staining in stroma tissues is shown under low and high magnifications.
Selection of the cutoff score for high expression of PD-L2
ROC curve analysis showed that stromal PD-L2 expression has some sort of predictive value in NPC, with the maximum area under the curve (AUC) reaching 0.618 (Figure 2E, red arrow). The points in curves with both maximum specificity and maximum sensitivity were treated as cutoff points for high or low stromal expression of PD-L2. For survival analysis, the cutoff score for stromal expression was 3.5 (Table 1). Thus, tumors designated as low expression of PD-L2 are those with scores below or equal to the cutoff score, while stroma cells of high expression are those with scores above the cutoff score. Using the same method, we obtained a cutoff value of 5.5 for PD-L2 in tumor tissues (Table 1 and supplemental Figure 1).
Figure 2.
Selection of the cutoff score. Receiver operating characteristic curve analysis was employed to determine the cutoff score for the designation of “high expression” of PD-L2. The sensitivity and specificity for each outcome of PD-L2 membranous staining of stromal tissues were plotted: A T classification (AUC=0.607, P =0.001); B N classification (AUC=0.571, P =0.120); C Clinical stage (AUC=0.612, P =0.002); D Cancer progression (AUC=0.610, P=0.001); E Survival status (AUC=0.618, P=0.001).
Table 1.
The corresponding cutoff score of PD-L2 stroma and tumor expression for each clinicopathological feature according to ROC curve analysis
| Feature | Cutoff score | P value |
|---|---|---|
| PD-L2 stroma expression | ||
| T classification | 4.5 | 0.001 |
| N classification | 1.5 | 0.120 |
| Clinical stage | 3.5 | 0.002 |
| Cancer progression | 2.5 | 0.001 |
| Survival status | 3.5 | 0.001 |
| PD-L2 tumor expression | ||
| T classification | 4.5 | 0.625 |
| N classification | 4.5 | 0.962 |
| Clinical stage | 4.5 | 0.675 |
| Cancer progression | 5.5 | 0.198 |
| Survival status | 5.5 | 0.399 |
Note: PD-L2, programmed death ligand-2; ROC, receiver operating characteristic.
Association of PD-L2 expression with clinicopathologic features and survival
NPC samples were separated into either low or high PD-L2 expression groups in tumor and stromal tissues respectively according to their expression levels to the cutoff. As a result, high stromal expression of PD-L2 was observed in 364/557 (65.4%) NPC tissues. With χ2-test analysis, we found that high stromal expression of PD-L2 was negatively correlated with age (Pearson's R=-0.108, P=0.011), tumor T classification (Pearson's R=-0.123, P=0.004), recurrence and metastasis (Pearson's R=-0.127 P=0.003) and clinical stage (Pearson's R=-0.111 P=0.009), respectively (Table 2), while there was no significant association with other clinicopathologic features, such as patient sex, N classification and histological type (P>0.05, Table 2). Among the 557 patients, non-keratinizing carcinoma accounted for 97.2% (including 402 NKUC and 139 NKDC) (supplemental Table 1). Therefore, only the correlation between PD-L2 expression and pathological types of 541 non-keratinizing carcinoma was analyzed. On the other hand, high tumor expression of PD-L2 was observed in 127/557 (22.8%) NPC tissues. Furthermore, we found that high tumor expression of PD-L2 was positively correlated with histological type (Pearson's R=0.171 P<0.001), but there was no significant association with other clinicopathologic features, such as age, sex, T classification, N classification, recurrence and metastasis and clinical stage (P>0.05, Table 3).
Table 2.
Association of PD-L2 expression and clinicopathological characteristics in NPC patients
| Characteristics | PD-L2 stroma staining | P value | Pearson's R | PD-L2 tumor staining | P value | Pearson's R | ||
|---|---|---|---|---|---|---|---|---|
| low (n=193) | high (n=364) | low (n=430) | high (n=127) | |||||
| Age, years | 0.011 | -0.108 | 0.231 | |||||
| <46 | 83 | 198 | 211 | 70 | ||||
| ≥46 | 110 | 166 | 219 | 57 | ||||
| Gender | 0.093 | 0.141 | ||||||
| Female | 40 | 102 | 104 | 38 | ||||
| Male | 153 | 262 | 326 | 89 | ||||
| Tumor stage | 0.004 | -0.123 | 0.501 | |||||
| T1+T2 | 59 | 157 | 170 | 46 | ||||
| T3+T4 | 134 | 207 | 260 | 81 | ||||
| Lymphoid Nodal (N) states | 0.258 | 0.947 | ||||||
| N0 | 45 | 101 | 113 | 33 | ||||
| N1-3 | 148 | 263 | 317 | 94 | ||||
| Recurrence/metastasis | 0.003 | -0.127 | 0.153 | |||||
| No | 113 | 236 | 282 | 67 | ||||
| Yes | 80 | 128 | 148 | 60 | ||||
| TNM clinical stage | 0.009 | -0.111 | 0.564 | |||||
| I+II | 38 | 109 | 116 | 31 | ||||
| III+IV | 155 | 255 | 314 | 96 | ||||
| Histological type | 0.095 | <0.001 | 0.171 | |||||
| NKUC | 147 | 255 | 328 | 74 | ||||
| NKDC | 38 | 101 | 91 | 48 | ||||
Note: PD-L2, programmed death ligand-2; NKUC, non-keratinizing undifferentiated carcinoma; NKDC, non-keratinizing differentiated carcinoma; KSCC, keratinizing squamous cell carcinoma, 16 cases of patients diagnosed with KSCC were not statistically analyzed.
Table 3.
Univariate Cox proportional hazards regression analysis for PD-L2
| 5 year OS | 95% CI | HR | P value | 5 year DFS | 95% CI | HR | P value | |
|---|---|---|---|---|---|---|---|---|
| Age | ||||||||
| <46 | 75.4% | Reference | 67.1% | Reference | ||||
| ≥46 | 62.0% | 1.261-2.316 | 1.709 | 0.001 | 58.0% | 1.046-1.809 | 1.375 | 0.022 |
| Sex | ||||||||
| Male | 67.9% | Reference | 60.8% | Reference | ||||
| Female | 71.0% | 0.626-1.268 | 0.891 | 0.52 | 68.1% | 0.550-1.071 | 0.768 | 0.12 |
| Clinical stage | ||||||||
| I+II | 92.5% | Reference | 85.7% | Reference | ||||
| III+IV | 60.1% | 3.535-11.993 | 6.511 | <0.001 | 54.3% | 2.532-6.245 | 3.976 | <0.001 |
| Tumor stage | ||||||||
| T1+T2 | 84.7% | Reference | 78.7% | Reference | ||||
| T3+T4 | 58.5% | 2.187-4.67 | 3.196 | <0.001 | 52.4% | 1.939-3.736 | 2.692 | <0.001 |
| Lymph node (N) status | ||||||||
| N0 | 80.1% | Reference | 72.6% | Reference | ||||
| N1-3 | 64.6% | 1.333-2.959 | 1.986 | <0.001 | 59.0% | 1.178-2.349 | 1.664 | 0.004 |
| Recurrence or metastasis status | ||||||||
| Yes | 28.6% | Reference | 14.3% | Reference | ||||
| No | 69.2% | 1.357-8.047 | 3.305 | 0.008 | 63.1% | 0.814-9.221 | 0.001 | |
| WHO histological classification | ||||||||
| NKUC | 69.8% | Reference | 62.6% | Reference | ||||
| NKDC | 67.6% | 0.885-1.570 | 1.179 | 0.261 | 64.0% | 0.918-2.083 | 1.302 | 0.885 |
| PD-L2 stroma expression | ||||||||
| Low | 60.1% | Reference | 53.4% | Reference | ||||
| High | 73.3% | 0.459-0.836 | 0.620 | 0.002 | 67.5% | 0.479-0.829 | 0.630 | 0.001 |
| PD-L2 tumor expression | ||||||||
| Low | 69.9% | Reference | 64.6% | Reference | ||||
| High | 64.6% | 0.922-1.817 | 1.294 | 0.137 | 55.9% | 1.000-1.846 | 1.359 | 0.048 |
Note: CI, confidence interval; WHO, World Health Organization; PD-L2, programmed death ligand-2; NKUC, non-keratinizing undifferentiated carcinoma; NKDC, non-keratinizing differentiated carcinoma; KSCC, keratinizing squamous cell carcinoma.
The 5-year overall and disease-free survival rates of the cohort of 557 NPC patients were 68.7% and 62.6%, respectively (Figure 3A and 3B). Of these 557 NPC patients, Kaplan-Meier and log-rank test analyses indicated that high stromal PD-L2 expression was significantly associated with favorable overall survival (OS) (5-year survival rates, 73.3% vs. 60.1%, log-rank test, X2 = 10.006, P = 0.002, Figure 3C) and disease-free survival (DFS) (5-year survival rates, 67.5% vs. 53.4%, log-rank test, X2=9.502, P=0.001, Figure 3D) compared with low stromal PD-L2 expression. When the clinical stages were taken as stratifications, the associations were much significantly stronger for patients at early stages (stage I-II), between stromal PD-L2 expression and good OS (5-year survival rates, 92.5% vs. 60.1%, log-rank test, X2=14.219, P<0.001, Figure 4A) and DFS (5-year survival rates, 85.7% vs. 54.3%, log-rank test, X2 = 11.883, P=0.001, Figure 4B), while the associations were not significant for patients at the late stages (stage III-IV; Figure 4C and 4D). In contrast, high tumor PD-L2 expression was negatively correlated with disease-free survival (P=0.048, Figure 3E), but there was no significant correlation between the tumor PD-L2 expression level and overall survival time (P=0.134, Figure 3F). However, high tumor PD-L2 expression also had a poor DFS prognostic value at late stages (stage III-IV) (5-year survival rates, 45.8% vs. 56.9%, log-rank test, X2 = 5.001, P=0.025, Figure 4H), while it had no prognostic value for OS and early-stage patients (Figure 4E-G).
Figure 3.
Association between PD-L2 expression and NPC patient survival. TMA analyses were conducted in a cohort of 557 NPC patients diagnosed at M0. A The five-year overall survival (OS) rate was 68.7%. B The five-year disease-free survival (DFS) rate was 62.6%. C and D High PD-L2 expression levels in stromal tissues were significantly associated with OS (P = 0.002) and disease-free survival (P = 0.001) in all NPC patients. F High PD-L2 expression levels in tumor tissues were significantly associated with disease-free survival (P = 0.048), and there were no significant differences in five-year OS (P = 0.134) in all NPC patients (E).
Figure 4.
Association between PD-L2 expression and NPC patient survival at different stages. A and B High PD-L2 expression in the stroma was significantly associated with OS (P < 0.001) and disease-free survival (P = 0.001) in NPC patients at early stages (I-II). C and D No significant differences in five-year OS and DFS rates were found between groups with low and high expression of PD-L2 in tumor tissues of NPC patients at early stages (I-II). E and F No significant differences in five-year OS and DFS rates were found between groups with low and high expression of PD-L2 in NPC patients at late stages (III-IV). H High PD-L2 expression levels in tumor tissues were significantly associated with disease-free survival (P = 0.025), and there were no significant differences in five-year OS in all NPC patients (G).
Independency test of the association between PD-L2 expression and survival
Univariate Cox proportional hazard regression analysis showed that PD-L2 stromal expression (P=0.002), age (P=0.001) and well-known clinicopathologic prognostic parameters, such as T classification (P<0.001), N classification (P=0.001), recurrence or metastasis (P=0.005) and clinical stage (P<0.001), were significantly associated with survival (Table 3). Moreover, independency tests were carried out among the prognostic factors, including PD-L2 stromal expression and other clinicopathologic features (age, T classification, N classification, recurrence or metastasis and clinical stage), under a multivariate Cox proportional hazards regression model. In multivariate statistical analysis, we choose overall survival time as “time”, overall survival status as “status”, “death” as the reference (with a value of 1). We found that stromal PD-L2 was an independent and favorable factor for overall and cancer progression survival (OS hazards ratio: 0.722; 95% confidence interval: 0.528-0.986; P=0.041; DFS hazards ratio: 0.744; 95% confidence interval: 0.559-0.99; P=0.042) (Table 4). In addition, age, recurrence or metastasis and clinical stage were found to be independent prognostic predictors for overall survival and cancer progression survival. In contrast, tumor PD-L2 was an independent and worse factor for cancer progression survival (DFS hazards ratio: 1.423; 95% confidence interval: 1.033-1.961; P=0.031) (Table 4).
Table 4.
Multivariate Cox proportional hazards regression analysis for PD-L2
| 5 year OS | 95% CI | HR | P value | 5 year DFS | 95% CI | HR | P value | |
|---|---|---|---|---|---|---|---|---|
| Age | ||||||||
| <46 | 75.4% | Reference | 66.4% | Reference | ||||
| ≥46 | 62.0% | 1.181-2.203 | 1.613 | 0.003 | 59.2% | 1.006-1.762 | 1.332 | 0.045 |
| Clinical stage | ||||||||
| I+II | 92.5% | Reference | 85.7% | Reference | ||||
| III+IV | 60.1% | 1.804-8.014 | 3.802 | <0.001 | 54.3% | 1.296-4.306 | 2.362 | 0.005 |
| Tumor stage | ||||||||
| T1+T2 | 84.7% | Reference | 78.7% | Reference | ||||
| T3+T4 | 58.5% | 0.976-2.476 | 1.554 | 0.063 | 52.4% | 1.000-2.374 | 1.541 | 0.050 |
| Lymph node (N) status | ||||||||
| N0 | 80.1% | Reference | 72.6% | Reference | ||||
| N1-3 | 64.6% | 1.051-2.385 | 1.583 | 0.028 | 59% | 0.986-2.007 | 1.406 | 0.060 |
| Recurrence or metastasis status | ||||||||
| Yes | 28.6% | Reference | 14.3% | Reference | ||||
| No | 69.2% | 0.951-6.397 | 2.466 | 0.063 | 63.1% | 1.205-6.623 | 2.825 | 0.017 |
| PD-L2 stroma expression | ||||||||
| Low | 60.1% | Reference | 53.4% | Reference | ||||
| High | 73.3% | 0.528-0.986 | 0.722 | 0.041 | 67.5% | 0.559-0.990 | 0.744 | 0.042 |
| PD-L2 tumor expression | ||||||||
| Low | 69.9% | Reference | 64.6% | Reference | ||||
| High | 64.6% | 0.917-1.875 | 1.311 | 0.138 | 55.9% | 1.033-1.961 | 1.423 | 0.031 |
Note: CI, confidence interval; PD-L2, programmed death ligand-2.
Correlations of PD-L2 expression and CD68+ macrophages and CD4+Foxp3+ Treg cells in NPC tissue
To elucidate the roles of PD-L2 in immune regulation, we analyzed the correlation between the expression of stroma and tumor PD-L2 with the number of CD68+ macrophages and CD4+Foxp3+ Treg cells in the tumor and stroma, respectively, which have been implicated in the tumor microenvironment of previous reports 18-19. Among 557 NPC tissues, high stromal PD-L2 expression was positively correlated with the infiltration of CD68+ macrophages (51.52 ± 24.41/HPF vs. 42.33 ± 22.74/HPF, Pearson correlation=0.181; P<0.0001) and CD4+Foxp3+ Treg cells (7.49 ± 3.8/HPF vs. 6.96 ± 4.59/HPF, Pearson correlation=0.098; P=0.021; Table 5) in stromal tissue.
Table 5.
Association between PD-L2 molecular expression and immune cell density
| CD68+ macrophagedensity in tumor | CD68+ macrophage density in stroma | CD4+Foxp3+ Treg density In stroma |
||
|---|---|---|---|---|
| PD-L2 tumor expression | Pearson Correlation | 0.005 | 0.054 | -0.007 |
| P value | 0.902 | 0.207 | 0.871 | |
| PD-L2 stroma expression | Pearson Correlation | 0.063 | 0.181 | 0.098 |
| P value | 0.139 | <0.0001 | 0.021 |
Discussion
Immune checkpoint inhibitors are the main strategies of immunotherapy and have been widely used in various solid tumors. EBV-associated NPC is one of the most common head and neck malignancies, and its unique immune environment with massive T-cell infiltration provides a reasonable target for immunotherapy. However, the clinical benefit of immunotherapy is limited to a small number of patients with T-cell responses 20. To overcome the bottleneck of immunotherapy based on PD-1 and PD-L1 and screen immunotherapy markers for advanced NPC patients, we analyzed the prognostic value of intratumoral and interstitial immune indicators for patients with nasopharyngeal cancer.
Here, we found that overexpression of PD-L2 protein is likely correlated with NPC. PD-L2 protein was expressed in 90.8% of NPC tumor tissues and 80.8% of stromal tissues. Interestingly, we observed that distinct PD-L2 expression patterns correlated with different clinical outcomes. High stromal expression of PD-L2 predicted an improved survival rate, whereas high tumor abundance of PD-L2 was correlated with a poor disease-free survival rate. Furthermore, under a multivariate Cox proportional hazards regression model, stromal PD-L2 was an independent and favorable factor for overall and cancer progression survival, while tumor PD-L2 was an independent and worse factor for cancer progression survival. More importantly, further correlation analyses revealed that high stromal expression of PD-L2 in NPC was negatively associated with tumor T classification, recurrence and metastasis and advanced clinical stage, which suggested that stromal PD-L2 plays an antitumor role, whereas tumor PD-L2 may provide a selective advantage in NPC tumorigenic processes.
PD-L2 is the second PD-1 ligand discovered after PD-L1, and its immune regulation is complex and controversial. By binding to PD-1 on the surface of activated T cells, PD-L2 transmits negative signals to inhibit the proliferation of T cells and the secretion of cytokines, thereby inhibiting the immune function of T cells 21. Studies have found that strong PD-L2 expression in a variety of tumor tissues can play a negative role in tumor immune escape and predict poor overall survival, such as in liver cancer 22, esophageal cancer 23, prostate cancer 24, bladder cancer 25 and lung adenocarcinoma 26. Its high expression refers to tumor infiltration depth, lymph node and tumor metastasis 22. In this study, we also found that high levels of PD-L2 in NPC tumor tissues were correlated with unfavorable disease-free survival.
On the other hand, PD-L2 can bind to other receptors and play an immune costimulatory role. A study showed that PD-L2 binds repulsive guidance molecules B (RGMb) with the new type to form a supercomplex, initiates a series of downstream events such as downstream target gene transcription and cytoskeletal recombination, mediates T-cell amplification, and then plays an immune-activating role 27. In this study, we found that the high expression of PD-L2 in NPC stromal was contrary to that in nest, and there was a significant positive correlation between PD-L2 expression level and tumor-free survival time and overall survival time. Recent studies have found that, in addition to the PD-1 receptor, PD-L2 can also be combined with the unknown second receptor. Under the combined effects of anti-CD3 antibody subdose, PD-L2 stimulated T-cell proliferation more significantly than B7-1 to significantly enhance antitumor immune response, and this function is considered to be the main function of PD-L2 28-29. Previous experiments have shown that NPC patients with high expression of macrophages and associated regulatory T lymphocytes have a good prognosis 18-19. Here, we found that the high expression of PD-L2 in the stroma significantly increased the number of tumor-related CD68+ macrophages and CD4+Foxp3+ Treg regulatory T lymphocytes. Thus, the role of PD-L2 in stromal cell expression is opposite to that in tumor cells and plays a positive costimulatory effect in NPC stoma tissue.
The differential effects of PD-L2 on tumor cells and stromal cells may be due to different biological roles resulting from the binding of different receptors. Tumor cells may be combined with PD-1 to play an immune escape role and promote tumor progression; however, stromal cells may contribute to an antitumor immune response by associating with the unknown second receptor. Current research on PD-L2 is still in the initial stage, but the development of a study of PD-L2 and its various receptors will help further explore the effect and mechanism of the tumor immune microenvironment in tumor occurrence and development and provide a new set of therapeutic strategies.
Supplementary Material
Supplementary figure and table.
Acknowledgments
This study was partially supported by the Natural Science Foundation of Hunan Province, China (2020JJ4539 and 2021JJ30610); the Key Guiding Project of Hunan Provincial Health Commission (202104101985); the Science and Technology Innovation Project of Hengyang City (202150064015); the University of South China Teaching Reform Research Project (2020YB-XJG127); and the National High Technology Research and Development Program of China (863 Program) (2012AA02A206).
Author Contributions
AX conducted the IHC experiments, wrote the initial draft. WJ revised the manuscript. SL and QY helped to perform some IHC experiments and follow-up of patients. HY, JX and QS performed IHC work. JY and YX participated in the study design and interpretation of the results. MB contributed to the study coordination and revisions. All authors read and approved the final manuscript.
References
- 1.Yu-Pei Chen, Anthony T C Chan, Quynh-Thu Le, Pierre Blanchard, Ying Sun, Jun Ma. Nasopharyngeal carcinoma. Lancet. 2019;394:64–80. doi: 10.1016/S0140-6736(19)30956-0. [DOI] [PubMed] [Google Scholar]
- 2.Chen Y-P, Yin J-H, Li W-F, Li H-J, Chen D-P, Zhang C-J. et al. Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. Cell Res. 2020;30:1024–42. doi: 10.1038/s41422-020-0374-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Anne W M Lee, Wai Tong Ng, Jimmy Y W Chan, June Corry, Antti Mäkitie, William M Mendenhall. et al. Management of locally recurrent nasopharyngeal carcinoma. Cancer Treat Rev. 2019;79:101890. doi: 10.1016/j.ctrv.2019.101890. [DOI] [PubMed] [Google Scholar]
- 4.Abdulaziz A Almobarak, Alaeddin B Jebreel, Ahmed Abu-Zaid. Molecular Targeted Therapy in the Management of Recurrent and Metastatic Nasopharyngeal Carcinoma: A Comprehensive Literature Review. Cureus. 2019;11:e4210. doi: 10.7759/cureus.4210. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Fang W, Yang Y, Ma Y, Hong S, Lin L, He X. et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018;19:1338–50. doi: 10.1016/S1470-2045(18)30495-9. [DOI] [PubMed] [Google Scholar]
- 6.Ma B, Lim W, Goh B. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic phase 2 consortium (NCI-9742) J Clin Oncol. 2018;36:1412–8. doi: 10.1200/JCO.2017.77.0388. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Hsu C, Lee S, Ejadi S. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol. 2017;35:4050–56. doi: 10.1200/JCO.2017.73.3675. [DOI] [PubMed] [Google Scholar]
- 8.Morgane Denis, Michael Duruisseaux, Marie Brevet, Charles Dumontet. How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors? Front Immunol. 2020;11:492. doi: 10.3389/fimmu.2020.00492. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Xiaofeng Liu, Chunguang Shan, Yingluan Song, Juan Du. Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1, 315 Patients. Front Oncol. 2019;9:1111. doi: 10.3389/fonc.2019.01111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Ying-Fei Li, Jian-Wu Ding, Ling-Min Liao, Zhi-Lin Zhang, Shou-Sheng Liao, Ying Wu. et al. Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma. Mol Clin Oncol. 2017;7:378–382. doi: 10.3892/mco.2017.1318. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Hayriye Sahinli, Nalan Akyürek, Mukaddes Yılmaz, Olcay Kandemir, Ayşe Ocak Duran, Sezer Kulaçoğlu. et al. PD-L1 expression in immune cells is a favorable prognostic factor for nasopharyngeal carcinoma. Indian J Cancer. 2021;58:561–66. doi: 10.4103/ijc.IJC_459_19. [DOI] [PubMed] [Google Scholar]
- 12.Zi-Lu Huang, Shan Liu, Guan-Nan Wang, Shuo-Han Zheng, Shi-Rong Ding, Ya-Lan Tao. et al. The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Cancer Cell Int. 2019;19:141. doi: 10.1186/s12935-019-0863-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Yiqi Xu, Zhenyue Gao, Ruxin Hu, Yuqing Wang, Yuhong Wang, Zheng Su. et al. PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy. J Immunother Cancer. 2021;9:e002699. doi: 10.1136/jitc-2021-002699. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Elena Muraro, Rebecca Romanò, Giuseppe Fanetti, Emanuela Vaccher, Irene Turturici, Valentina Lupato. et al. Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncology. Crit Rev Oncol Hematol. 2022;175:103707. doi: 10.1016/j.critrevonc.2022.103707. [DOI] [PubMed] [Google Scholar]
- 15.Liu LN, Huang PY, Lin ZR, Hu LJ, Liang JZ, Li MZ. et al. Protein tyrosine kinase 6 is associated with nasopharyngeal carcinoma poor prognosis and metastasis. J Transl Med. 2013;11:140. doi: 10.1186/1479-5876-11-140. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Wang HY, Sun BY, Zhu ZH, Chang ET, To KF, Hwang JS. et al. Eight-Signature Classifier for Prediction of Nasopharyngeal Carcinoma Survival. J Clin Onco. 2011;29:4516–25. doi: 10.1200/JCO.2010.33.7741. [DOI] [PubMed] [Google Scholar]
- 17.Cai MY, Zhang B, He WP, Yang GF, Rao HL, Rao ZY. et al. Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer Sci. 2010;101:1543–9. doi: 10.1111/j.1349-7006.2010.01560.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Yahui Yu, Liangru Ke, Wei-Xiong Xia, Yanqun Xiang, Xing Lv, Junguo Bu. Elevated Levels of TNF-α and Decreased Levels of CD68-Positive Macrophages in Primary Tumor Tissues Are Unfavorable for the Survival of Patients With Nasopharyngeal Carcinoma. Technol Cancer Res Treat. 2019;18:1533033819874807. doi: 10.1177/1533033819874807. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.WK Yip, MA Abdullah, SM Yusoff, HF Seow. Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced zeta-chain expression in nasopharyngeal carcinoma patients. Clin Exp Immunol. 2009;155:412–22. doi: 10.1111/j.1365-2249.2008.03793.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Eugenia L L Yeo, You Quan Li, Khee-Chee Soo, Joseph T S Wee, Melvin L K Chua.Combinatorial strategies of radiotherapy, immunotherapy in nasopharyngeal carcinoma. Chin Clin Oncol. 2018;7:15.
- 21.Boussiotis VA, Chatterjee P, Li L. Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J. 2014;20:265–271. doi: 10.1097/PPO.0000000000000059. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Xiaochun Lin, Kunpeng Lin, Chunxuan Lin, Jiakang Wang, Yunqiang Tang. Prognostic and clinicopathological utility of PD-L2 expression in patients with digestive system cancers: A meta-analysis. Int Immunopharmacol. 2020;88:106946. doi: 10.1016/j.intimp.2020.106946. [DOI] [PubMed] [Google Scholar]
- 23.Kazuo Okadome, Yoshifumi Baba, Daichi Nomoto, Taisuke Yagi, Rebecca Kalikawe, Kazuto Harada. et al. Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers. Br J Cancer. 2020;122:1535–43. doi: 10.1038/s41416-020-0811-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Shuang G Zhao, Jonathan Lehrer, S Laura Chang, Rajdeep Das, Nicholas Erho, Yang Liu. et al. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. J Natl Cancer Inst. 2019;111:301–10. doi: 10.1093/jnci/djy141. [DOI] [PubMed] [Google Scholar]
- 25.Yubo Yang, Xiaoming Wang, Yunjin Bai, Dechao Feng, Ao Li, Yin Tang. et al. Programmed death-ligand 2 (PD-L2) expression in bladder cancer. Urol Oncol. 2020;38:603.e9–603.e15. doi: 10.1016/j.urolonc.2020.01.001. [DOI] [PubMed] [Google Scholar]
- 26.Xiaochun Lin, Kunpeng Lin, Chunxuan Lin, Taisheng Liu, Mingchen Ba, Yunqiang Tang. et al. Prognostic and clinicopathological value of PD-L2 in lung cancer: A meta-analysis. Int Immunopharmacol. 2021;91:107280. doi: 10.1016/j.intimp.2020.107280. [DOI] [PubMed] [Google Scholar]
- 27.Xiao Y, Yu S, Zhu B. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med. 2014. pp. 211943–59. [DOI] [PMC free article] [PubMed]
- 28.Radhakrishnan S, Nguyen LT, Ciric B. Immunotherapeutic potential of B7-DC (PD-L2) cross-linking antibody in conferring antitumor immunity. Cancer Res. 2004;64:4965–72. doi: 10.1158/0008-5472.CAN-03-3025. [DOI] [PubMed] [Google Scholar]
- 29.Liu X, Gao JX, Wen J. B7DC/PD-L2 promotes tumor immunity by a PD- 12 independent mechanism. Exp Med. 2003;197:1721–30. doi: 10.1084/jem.20022089. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supplementary figure and table.